BioSyent sees 14% rise in Q3 sales
Sales in first nine months of 2010 were $1,216,019
BioSyent, a specialty pharmaceutical company, has reported total sales of $616,964 in Q3 2010, an increase of 14%, compared to $540,870 in Q3 2009.
The sales in the first nine months of 2010 were $1,216,019 compared to $911,543 in the corresponding previous year period.
BioSyent incurred a loss of $31,987 in the first nine months of 2010, 64% lower than a loss of $90,146 in the first nine months of 2009.
BioSyent said that it continues to concentrate on its pharmaceutical strategy to source products that have been developed and proven to be safe and effective; manage these products through the regulatory process and product registration; and once approved, market these products in Canada.